Opinion of the Transparency Council – diazepamum

At its meeting on 1 July 2024, the Transparency Council adopted opinion No. 102/2024 on the inclusion in the reimbursement of medicines containing the active substance diazepamum in the scope of indications for use or dosage or method of administration different from those specified in the Summary of Product Characteristics of Medicinal Products

Publication on the list of opinions on active substances for off-label indications >>